Edem S Agamah MD

Oncology•Springfield, IL

Central Illinois Hematology Oncology Center

Join to View Full Profile

315 W Carpenter St# 1BSpringfield, IL 62702
Phone+1 217-545-8000
Fax+1 217-545-1141

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1993 - 1995
Ascension Illinois/Saint FrancisResidency, Internal Medicine, 1990 - 1993
University of Ghana Medical SchoolClass of 1985

Certifications & Licensure

IL State Medical License 1992 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2001

Clinical Trials

Decitabine in Treating Patients With Myelofibrosis Start of enrollment: 2004 Sep 29
ACTIVE_NOT_RECRUITING
PHASE2
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Start of enrollment: 2008 Jun 01
Completed
Phase 1
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Start of enrollment: 2008 Dec 01
Terminated
Phase 2
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Start of enrollment: 2009 Mar 16
Completed
Phase 2
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Start of enrollment: 2009 Sep 01
Completed
Phase 2
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Start of enrollment: 2009 Aug 01
Completed
Phase 1
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Start of enrollment: 2009 Sep 03
COMPLETED
PHASE2
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2010 Apr 15
Completed
Phase 1, Phase 2
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery Start of enrollment: 2010 Oct 01
Terminated
Phase 2
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel Start of enrollment: 2010 Oct 01
Completed
Phase 2
Saracatinib in Treating Patients With Prostate Cancer Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2011 Jun 20
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

3 citations
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.
Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, Carl M Gay, Lauren A Byers
Journal of Thoracic Oncology. 2025-03-01
76 citations
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adren...
Antonio M. Lerario, Francis P. Worden, Carole A. Ramm, Elizabeth Hesseltine, Walter M. Stadler
Hormones & Cancer. 2014-05-22
46 citations
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Nicholas P. Campbell, Rangesh Kunnavakkam, Natasha B. Leighl, Mark Vincent, David R. Gandara
Lung Cancer. 2012-10-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Fellow